[go: up one dir, main page]

AR105539A1 - Potenciamiento de la respuesta inmunológica en especies acuáticas - Google Patents

Potenciamiento de la respuesta inmunológica en especies acuáticas

Info

Publication number
AR105539A1
AR105539A1 ARP160102324A ARP160102324A AR105539A1 AR 105539 A1 AR105539 A1 AR 105539A1 AR P160102324 A ARP160102324 A AR P160102324A AR P160102324 A ARP160102324 A AR P160102324A AR 105539 A1 AR105539 A1 AR 105539A1
Authority
AR
Argentina
Prior art keywords
aquatic species
improvement
immune response
cpg motif
immunomodulatory composition
Prior art date
Application number
ARP160102324A
Other languages
English (en)
Inventor
Dr Koesling Jan
C Simard Nathalie
Dr Weiss Christian
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of AR105539A1 publication Critical patent/AR105539A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un método para generar una respuesta inmunológica en un sujeto receptor de una especie acuática comprende: a) administrar una cantidad efectiva de una composición inmunomoduladora a un sujeto de una especie acuática, en donde la composición inmunomoduladora comprende una secuencia de ácido nucleico que comprende por lo menos un motivo CpG inmunoestimulador, por lo menos un motivo CpG no inmunoestimulador, y un liposoma catiónico.
ARP160102324A 2015-07-31 2016-07-29 Potenciamiento de la respuesta inmunológica en especies acuáticas AR105539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562199840P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
AR105539A1 true AR105539A1 (es) 2017-10-11

Family

ID=56571309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102324A AR105539A1 (es) 2015-07-31 2016-07-29 Potenciamiento de la respuesta inmunológica en especies acuáticas

Country Status (13)

Country Link
US (1) US20190008952A1 (es)
EP (1) EP3328423B1 (es)
JP (1) JP2018521108A (es)
KR (1) KR20180035860A (es)
CN (1) CN108712912B (es)
AR (1) AR105539A1 (es)
AU (1) AU2016304343A1 (es)
CA (1) CA2994039A1 (es)
CL (1) CL2018000201A1 (es)
DK (1) DK3328423T3 (es)
IL (1) IL256947A (es)
TW (1) TWI733688B (es)
WO (1) WO2017021242A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017301528A1 (en) 2016-07-26 2019-02-14 Elanco Animal Health Gmbh Increased fertility in bovine species

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
EP1077708A1 (en) * 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
JP5759890B2 (ja) * 2008-03-25 2015-08-05 ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強
MX336019B (es) * 2009-05-14 2016-01-06 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares.
FR2964569B1 (fr) * 2010-09-10 2012-10-19 Ct De Cooperation Internationale En Rech Agronomique Pour Le Dev Cirad Nouveaux liposomes de vaccination genique
BR112013016231B1 (pt) * 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids

Also Published As

Publication number Publication date
CN108712912A (zh) 2018-10-26
EP3328423A1 (en) 2018-06-06
EP3328423B1 (en) 2021-05-26
JP2018521108A (ja) 2018-08-02
AU2016304343A1 (en) 2018-02-08
WO2017021242A1 (en) 2017-02-09
TW201718006A (zh) 2017-06-01
CN108712912B (zh) 2022-05-10
IL256947A (en) 2018-03-29
DK3328423T3 (da) 2021-07-26
KR20180035860A (ko) 2018-04-06
CA2994039A1 (en) 2017-02-09
CL2018000201A1 (es) 2018-07-13
US20190008952A1 (en) 2019-01-10
TWI733688B (zh) 2021-07-21

Similar Documents

Publication Publication Date Title
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
CY1125211T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2019008303A (es) Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
EP4501318A3 (en) Nucleic acid vaccines
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
EP4043031A3 (en) Zika viral antigen constructs
ZA202403393B (en) Synthetic chimeric poxviruses
PH12020550903A1 (en) Immunostimulatory compositions
WO2017152146A3 (en) Compositions and methods for inducing hiv-1 antibodies
BR112017005524A2 (pt) segmentos de rna viral como agentes imunomoduladores e componentes de vacina
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
NZ735362A (en) Lipid compositions
DOP2016000223A (es) Plásmidos inmunoestimuladores
MX390304B (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
MX377258B (es) Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria.
EP3939604A3 (en) Influenza hemagglutinin protein vaccines

Legal Events

Date Code Title Description
FG Grant, registration